Many of today’s educators, senior investigators, and thought leaders in the study of epilepsy were supported in their early careers with financial assistance from the Epilepsy Foundation.
Epilepsy Foundation Vision
To create a world without epilepsy and lives free from seizures and side effects.
Our purpose is to accelerate the development of therapies for people living with epilepsy.
In 2016, we surveyed the community asking what frustrated you most about epilepsy research & care.
You spoke. We listened.
Invest in Innovation, Next Generation Scientists, & Engagement with Stakeholders
You said: "After all these years, research seems to be slow,"– 2016 Community Survey
Our response: Invest in Innovation – We test new ideas and follow new research leads by:
- Pushing new ideas for epilepsy care and cures with the Epilepsy Innovation Institute
- Getting ideas connected to inventors and investors and developing new therapists faster with our Epilepsy Innovation Institute & Epilepsy Therapy Project
- Promoting research for the topics you care about, like SUDEP or Cannabidiol, with our Targeted Research Programs
You said: "Lack of funding and research," – 2016 Community Survey
Our response: Next Generation Scientists – We invest in our future by:
- Funding young researchers to bring their ideas to life through NextGen Researchers
You said: "There are no doctors that have experience here," – 2016 Community Survey
Our response: Engagement — Improve communications between people with epilepsy, their families, advocates, researchers, and investors.
- Connecting people with epilepsy to clinical trials via our Clinical Trial Portal
- Creating a learning network and databank through the Rare Epilepsy Network
- Working with regulators and industry to get therapies to the market faster with our Research Roundtable
- Hosting the Pipeline Conference to showcase the epilepsy pipeline to funders & the community at large
- Educating the community of new research developments through our new upcoming Hot Topics page & the Epilepsy Pipeline
- In 2017, the Epilepsy Therapy Project is supporting the first genetic therapy (Ataluren) for epilepsy.
"Support from the Epilepsy Foundation has allowed the first trial of a genetic therapy in epilepsy."
— Orrin Devinsky, MD
- In 2013, the Epilepsy Therapy Project supported the first Epidiolex® (CBD) trial by GW Pharma for Dravet and Lennox-Gastaut.
"The origin of the Epidiolex trial began with a pivotal meeting of researchers from across the US and representatives of the Epilepsy Foundation."
— Orrin Devinsky, MD
- In 2011, the SharkTank award went to SAMiTM by HiPass Designs for developing a sleep activity monitor to detect abnormal movements in the night.
"Winning the first Epilepsy Foundation Shark Tank Competition in 2011 allowed me to transform SAMi from an expensive custom solution for us into a refined, much less costly tool for others."
— Charles W. Anderson, President HiPass Designs
- In 2011 the Epilepsy Therapy Project supported the development of Visualase® by Medtronic. Visualase is an MRI-Guided Laser Ablation Technology for Minimally Invasive Neurosurgery to reduce the risk of open-brain surgery for people living with epilepsy.
"Aside from the funding, validation by ETP experts who vetted our project, and found it to be a worthwhile pursuit, has been a significant factor in our rapid progress and expansion into new centers."
— Ashok Gowda, PhD, Founder of Visualase, Inc — acquired by Medtronic in 2014, President & CEO BioTex, Inc.
- In 2009 and 2011, the Epilepsy Therapy Project funded the development of SmartWatch by Smart Monitor. This was one of the first watches to fuse sensor, mobile, and cloud technologies with big-data analytics to create an ease of use monitoring and alert system device for people living with epilepsy.
- In 2008, the Epilepsy Therapy Project supported the early clinical studies of Dr. Christopher De Giorgio at UCLA for testing the Monarch eTNS device, a new noninvasive nerve stimulation device, to stop seizures. Those studies paved the way for the Monarch eTNS device to obtain approval by the European Union. Currently, Monarch eTNS, by Neurosigma, is being reviewed by the FDA.
We won't stop until there are no seizures and no side effects. Our purpose is to accelerate the development of therapies for people living with epilepsy.
Join us in achieving this goal by supporting research at the Epilepsy Foundation.